.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Dow
Fish and Richardson
Chubb
Deloitte
Covington
Medtronic
Johnson and Johnson
QuintilesIMS
Farmers Insurance

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:SSEA-3 pluripotent stem cell isolated from body tissue
Abstract: Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue.
Inventor(s): Dezawa; Mari (Miyagi, JP), Fujiyoshi; Yoshinori (Kyoto, JP), Nabeshima; Youichi (Kyoto, JP), Wakao; Shohei (Miyagi, JP)
Assignee:
Application Number:12/836,264
Patent Claims:1. A method for enriching for human cells isolated from mesodermal or mesenchymal tissue of a living mammalian body, the method comprising (a) isolating human mesodermal or human mesenchymal cells that express SSEA-3 from human mesodermal or mesenchymal cells; and (b) collecting the SSEA-3 (+) human cells which comprise SSEA-3(+) human cells which are capable of forming cell clusters, the cell clusters including SSEA-3(+) human cells which: (i) exhibit low or no telomerase activity; (ii) are capable of differentiating into three germ layers; (iii) exhibit the lack of neoplastic proliferation; (iv) exhibit self-renewal capability; (v) are CD31 (-); (vi) are CD105(+); and (c) enriching the SSEA-3(+) human cells which exhibits (i) to (vi) above.

2. The method according to claim 1, wherein the human cell further has the following properties: (i) being negative for CD117 and negative for CD146; (ii) being negative for CD117, negative for CD146, negative for NG2, negative for CD34, negative for vWF, and negative for CD271; (iii) being negative for CD34, negative for CD117, negative for CD146, negative for CD271, negative for NG2, negative for vWF, negative for Sox10, negative for Snail, negative for Slug, negative for Tyrp1, and negative for Dct; and (iv) having low or no telomerase activity.

3. A method for enriching human cells isolated from mesodermal or mesenchymal tissue of a living mammalian body, the method comprising: (a) exposing a population of human mesodermal or human mesenchymal cells to cellular stress which is dispase or collagenase incubation; (b) collecting surviving cells which comprises at least 9% of human cells which can form cell clusters, the cell clusters including cells which comprise the following phenotypes: (i) are SSEA-3 (+); (ii) exhibit low or no telomerase activity; (iii) exhibit a lack of neoplastic proliferation; (iv) exhibit self-renewal capability; (v) exhibit a lack of CD31 expression or CD31 (-); (vi) are CD105(+); and (c) enriching the human cells which comprises phenotypes (i) to (vi) above.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Advance Biofactures
SANTYL
collagenase
VIAL1019950011965-06-04► Subscribe Dezawa; Mari (Miyagi, JP), Fujiyoshi; Yoshinori (Kyoto, JP), Nabeshima; Youichi (Kyoto, JP), Wakao; Shohei (Miyagi, JP) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Australia2010271722Jul 03, 2014
Australia2010271722Mar 01, 2012
Australia2010271722May 29, 2014
Canada2768238Jan 20, 2011
China102858951Dec 07, 2016
China102858951Jan 02, 2013
China103442724Dec 11, 2013
China103459590Dec 18, 2013
China107012117Aug 04, 2017
European Patent Office2455452May 23, 2012
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Healthtrust
US Army
Julphar
Mallinckrodt
Chubb
Cantor Fitzgerald
Farmers Insurance
US Department of Justice
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot